Company to provide update and host conference call today on clinical data to be presented at 2017 ASCO and EHA Meetings

 

ROCKVILLE, Md. --  GlycoMimetics, Inc. (NASDAQ: GLYC) today announced the release of abstracts containing new data from the ongoing Phase 2 clinical trial of its product candidate GMI-1271, an E-selectin antagonist, in patients with acute myeloid leukemia (AML). The data will be presented at the June annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA). The data released by ASCO and EHA, which reflect a late-January analysis, will be updated in posters presented at both meetings.

-- Additional Positive Results Support Rapid Advancement to Phase 3 Trial --

 

SEATTLE -- Omeros Corporation (NASDAQ: OMER) today announced completion of the IgA nephropathy cohort and reported additional positive results from the first stage of the company’s Phase 2 clinical trial of OMS721 for the treatment of serious kidney disorders. All patients in the cohort have now completed the OMS721 treatment and follow-up periods. The additional Phase 2 results in IgA nephropathy patients expand on the data reported earlier this year and further demonstrate marked and statistically significant improvement in urine protein levels (proteinuria). Proteinuria reduction is associated with slowing progression of kidney functional loss, and greater proteinuria reductions are associated with progressively better prognoses. OMS721 is Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the complement system’s lectin pathway.

Mr. Gilles Gagnon reports: CEAPRO INC. REPORTS 2017 FIRST QUARTER DEVELOPMENT HIGHLIGHTS AND FINANCIAL RESULTS

 

Ceapro Inc. has released its financial results for the three months ended March 31, 2017, and provided a corporate update.

Financial Highlights for the First Quarter 2017

 

Total sales of $3,183,000 for the quarter ended March 31, 2017 compared to $4,064,000 in Q1 2016;

Gross margin of $1,711,000 for the quarter ended March 31, 2017 compared to $2,834,000 in Q1 2016;

Income from operations of $193,000 for the quarter ended March 31, 2017 compared to $1,910,000 in Q1 2016;

Advancing a new potential therapeutic paradigm for the treatment of negative symptoms, a key unmet need in schizophrenia and other brain diseases

 

Company to host conference call on May 16, 2017 at 10:30 a.m. eastern time

 

WALTHAM, Mass., May 15, 2017  -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced plans for its Phase 3 and Phase 4 clinical development of MIN-101, a drug targeting negative symptoms in schizophrenia patients.  Following a recent “end-of-Phase 2” meeting with the U.S. Food and Drug Administration (FDA), the Company’s next step is the planned initiation of a pivotal Phase 3 trial with MIN-101 in the second half of 2017.